ZJSTIC, insurance industry leaders invest over $2M to support Anpac’s CDA technology

Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer Dr. Chris Yu announced that Venture Capital (VC) Firm, Shanghai Zhangjiang Science &Technology Investment Corporation (ZJSTIC), as well as private investors related to the insurance industry, have again invested over $2 Million to support Anpac’s “Cancer Differentiation Analysis” (CDA) technology.

Read more 0 Comments